Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 571,300 shares, a decrease of 26.5% from the January 31st total of 777,800 shares. Based on an average daily volume of 246,400 shares, the short-interest ratio is currently 2.3 days.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on the stock. Chardan Capital reissued a "buy" rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research report on Friday, November 15th. HC Wainwright restated a "buy" rating and set a $6.00 price objective on shares of Clearside Biomedical in a report on Thursday. Needham & Company LLC reissued a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a research report on Thursday. Finally, StockNews.com upgraded Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Thursday, December 12th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.
Get Our Latest Report on CLSD
Clearside Biomedical Stock Up 14.8 %
Shares of Clearside Biomedical stock traded up $0.13 on Thursday, reaching $0.98. The stock had a trading volume of 958,908 shares, compared to its average volume of 399,951. The stock has a market capitalization of $74.03 million, a P/E ratio of -2.17 and a beta of 2.10. The company has a 50 day moving average price of $0.96 and a 200 day moving average price of $1.06. Clearside Biomedical has a 1 year low of $0.77 and a 1 year high of $2.12.
Institutional Trading of Clearside Biomedical
A number of institutional investors have recently made changes to their positions in CLSD. Investor s Fiduciary Advisor Network LLC purchased a new stake in Clearside Biomedical in the fourth quarter valued at about $32,000. Northern Trust Corp grew its position in Clearside Biomedical by 24.0% during the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company's stock worth $157,000 after purchasing an additional 32,048 shares during the last quarter. Geode Capital Management LLC increased its stake in Clearside Biomedical by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 764,058 shares of the company's stock valued at $726,000 after purchasing an additional 32,672 shares in the last quarter. Finally, Johnson & Johnson purchased a new position in Clearside Biomedical in the 3rd quarter worth $105,000. Institutional investors and hedge funds own 18.75% of the company's stock.
About Clearside Biomedical
(
Get Free Report)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
See Also
Before you consider Clearside Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.
While Clearside Biomedical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
